To Analyze the Effect of Hemodialysis, Hemoperfusion, and Oral Olanzapine on Uremic Encephalopathy

Objective: To analyze the effects of hemodialysis, hemoperfusion, and oral olanzapine in patients with uremic encephalopathy. Methods: 70 patients with uremic encephalopathy admitted to the hospital from January 2023 to August 2024 were selected and divided into groups according to a random drawing method, with 35 cases in each group. The control group was treated with hemodialysis and olanzapine orally, and the observation group was treated with hemoperfusion. PANSS scores, biochemical indexes, and inflammatory factors were compared between the two groups. Results: PANSS score, biochemical indexes, and inflammatory factors in the observation group were significantly lower than those in the control group (P < 0.05). Conclusion: The triple therapy of hemodialysis, hemoperfusion, and olanzapine can obviously promote the improvement of the psychological state of the patients. In addition, this treatment can also relieve inflammation in the patients and accelerate the excretion of toxins in the body.